share_log

Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference

Earnings Call Summary | ELSE NUTRITION HOLDINGS INC(BABYF.US) Q1 2024 Earnings Conference

業績電話會議摘要 | ELSE NUTRITION HOLDINGS INC (BABYF.US) 2024 年第一季度業績發佈會
moomoo AI ·  05/18 16:45  · 電話會議

The following is a summary of the Else Nutrition Holdings Inc. (BABYF) Q1 2024 Earnings Call Transcript:

以下是Else Nutrition Holdings Inc.(BABYF)2024年第一季度業績電話會議記錄摘要:

Financial Performance:

財務業績:

  • Else Nutrition Holdings reported a Q1 2024 revenue of $2.1 million, a drop from $2.9 million in Q1 2023.

  • Despite a decrease in the quarter revenue due to anticipated customer deal delays, the company expects to see significant revenue growth throughout 2024.

  • The company saw a 92% increase in U.S. Amazon sales and a 330% increase in Canadian Amazon sales compared to the same period in 2023.

  • Else Nutrition Holdings報告稱,2024年第一季度收入爲210萬美元,低於2023年第一季度的290萬美元。

  • 儘管由於預期的客戶交易延遲,本季度收入有所下降,但該公司預計2024年全年收入將大幅增長。

  • 與2023年同期相比,該公司在美國的亞馬遜銷售額增長了92%,加拿大亞馬遜的銷售額增長了330%。

Business Progress:

業務進展:

  • Else Nutrition started 2024 on a high note, with several retail partner announcements and launching their kids ready-to-drink shakes in both vanilla and chocolate flavors.

  • They are preparing to introduce an adult ready-to-drink line.

  • With the commercial launch of their plant-based infant formula in Australia, they are entering a growing market.

  • They have secured three manufacturing partners and signed a powder manufacturing agreement to guarantee supply through the end of 2025.

  • A new marketing program is underway to broaden brand recognition and fuel growth.

  • They are continually liaising with the FDA for U.S. approval based on the rising global demand for plant-based products.

  • Else Nutrition在2024年開局時表現強勁,宣佈了幾家零售合作伙伴,並推出了香草和巧克力口味的兒童即飲奶昔。

  • 他們正準備推出成人即飲產品線。

  • 隨着其植物性嬰兒配方奶粉在澳大利亞的商業推出,他們正在進入一個不斷增長的市場。

  • 他們已經找到了三個製造合作伙伴,並簽署了粉末製造協議,以保證2025年底之前的供應。

  • 一項新的營銷計劃正在進行中,以擴大品牌知名度並推動增長。

  • 鑑於全球對植物基產品的需求不斷增加,他們一直在與美國食品藥品管理局聯絡,爭取美國的批准。

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論